The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
CD19, a B cell–restricted receptor critical for B-cell development, is expressed in most B-cell malignancies. The Fc-engineered anti-CD19 antibody, XmAb5574, has enhanced Fcγ receptor (FcγR) binding affinity, leading to improved FcγR-dependent effector cell functions and antitumor activity in murine xenografts compared with the non–Fc-engineered anti-CD19 IgG1 analog. Here, we use XmAb5574 and anti-CD19 IgG1 to further dissect effector cell functions in an immune system closely homologous to that of humans, the cynomolgus monkey. XmAb5574 infusion caused an immediate and dose-related B-cell depletion in the blood (to <10% of baseline levels) concomitant with a sustained reduction of natural killer (NK) cells. NK cells had fully recovered by day 15, whereas B-cell recovery was underway by day 57. B cells in secondary lymphoid tissues were depleted (to 34%-61% of vehicle), with involuted germinal centers apparent in the spleen. Anti-CD19 IgG1 had comparable serum exposure to XmAb5574 but demonstrated no B-cell depletion and no sustained NK-cell reduction. Thus, increasing FcγR binding affinity dramatically increased B-cell clearing. We propose that effector cell functions, possibly those involving NK cells, mediate XmAb5574 potency in cynomolgus monkeys, and that enhancing these mechanisms should advance the treatment of B-cell malignancies in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“severely reduced both the B-cell depleting activity of anti-CD20 (rituximab) and the tumor killing activity of anti-HER-2/neu (trastuzumab).(19,20) Studies of human genetic polymorphisms have demonstrated a relationship between increased FcγR affinity for the immunotherapeutic and improved clinical outcome.”
BackgroundTumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078 · cited 2×
“Such mice fail to develop a proper immune response after antigen challenge, exhibit decreased B-cell numbers in the periphery and in lymphoid tissues, lack germinal center (GC) formation, and have decreased serum immunoglobulin (Ig) levels.1,3,4 Furthermore, anti-CD19 antibodies effectively deplete peripheral B cells…”
ResultMusolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“exhibited improved progression-free survival when compared with patients expressing the lower affinity 158F allele when treated with rituximab or trastuzumab.(21,22) Together, these human and murine data substantiate the importance of immune effector-mediated mechanisms in the efficacy of immunotherapeutics.”
Background
Cited by
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Reduced elimination of IgG antibodies by engineering the variable region
Igawa, T., Tsunoda, H., Tachibana, T., Maeda, A., Mimoto, F., Moriyama, C., Nanami, M., Sekimori, Y., Nabuchi, Y., Aso, Y., et al. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq009 · Cited by 265
Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications
Levy, E. M., Roberti, M. P., & Mordoh, J. (2011) · BioMed Research International · doi:10.1155/2011/676198 · Cited by 219
“The in vivo infusion of this high affinity MAb efficiently cleared malignant B cells in cynomolgus macaques (Macaca fascicularis) [50].”
BackgroundCD19: a promising B cell target for rheumatoid arthritis
Tedder, T. F. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.184 · Cited by 187
“XmAb ® 5574 given to cynomolgus monkeys causes a dose-dependent, rapid, and extensive (95%) clearance of circulating B cells, as well as a 65–82% reduction in lymphoid tissue B cells”
Background
Metadata
- Authors
- Zalevsky, J., Leung, I. W. L., Karki, S., Chu, S. Y., Zhukovsky, E. A., Desjarlais, J. R., Carmichael, D. F., & Lawrence, C. E.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-04-16
- Volume
- 113
- Issue
- 16
- Pages
- 3735-3743
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2059917238
- Cited by
- 101
- References
- 3
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates. https://app.cochat.ai/papers/10.1182/blood-2008-10-182048
- The paper
- Zalevsky, J., Leung, I. W. L., Karki, S., Chu, S. Y., Zhukovsky, E. A., Desjarlais, J. R., Carmichael, D. F., & Lawrence, C. E. (2009). The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates. Blood. https://doi.org/10.1182/blood-2008-10-182048
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.